Polymorphisms in androgen signaling pathway predisposing to prostate cancer

Molecular and Cellular Endocrinology

Volumn 360, Issue 1-2, 2012, Pages 25-37

  Schleutker, Johanna ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Androgen signaling pathway; Cancer etiology; Polymorphism; Prostate cancer; Risk; Variant

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ANDROGEN RECEPTOR; AROMATASE; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME P450 17; CYTOCHROME P450 3A; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; SULFOTRANSFERASE 1A1; TESTOSTERONE 17BETA DEHYDROGENASE;

AKR1C GENE; ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; AR GENE; ATTITUDE TO HEALTH; CANCER RISK; CANCER SUSCEPTIBILITY; CYP11A1 GENE; CYP17A1 GENE; CYP19A1 GENE; CYP3A GENE; ETHNIC DIFFERENCE; GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC PROCEDURES; GENOTYPE ENVIRONMENT INTERACTION; HSD17B GENE; HSD3B GENE; HUMAN; LHB GENE; POPULATION RESEARCH; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SHBG GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SRD5A1 GENE; SRD5A2 GENE; SULT2A1 GENE; TESTOSTERONE METABOLISM; UGT2B15 GENE; UGT2B17 GENE;

ANDROGENS; BIOSYNTHETIC PATHWAYS; GENETIC PREDISPOSITION TO DISEASE; GLUCURONOSYLTRANSFERASE; HUMANS; HYDROXYSTEROID DEHYDROGENASES; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SEX HORMONE-BINDING GLOBULIN; STEROID HYDROXYLASES; SULFOTRANSFERASES; TESTOSTERONE;

EID: 84864004900     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.07.007     Document Type: Review

References (108)

1. Allen N.E., Forrest M.S., Key T.J. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol. Biomarkers Prev. 2001, 10:185-189.
2. Allen N.E., Reichardt J.K., Nguyen H., Key T.J. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men. Cancer Epidemiol. Biomarkers Prev. 2003, 12:578-581.
3. Bangsi D., Zhou J., Sun Y., Patel N.P., Darga L.L., Heilbrun L.K., Powell I.J., Severson R.K., Everson R.B. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol. Oncol. 2006, 24:21-27.
4. Barbier O., Lapointe H., El Alfy M., Hum D.W., Bélanger A. Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistochemistry. J. Clin. Endocrinol. Metab. 2000, 85:4819-4826.
5. Beilin J., Ball E.M., Favaloro J.M., Zajac J.D. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J. Mol. Endocrinol. 2000, 25:85-96.
6. Berndt S.I., Chatterjee N., Huang W.Y., Chanock S.J., Welch R., Crawford E.D., Hayes R.B. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2007, 16:165-168.
7. Beuten J., Gelfond J.A., Franke J.L., Weldon K.S., Crandall A.C., Johnson-Pais T.L., Thompson I.M., Leach R.J. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2009, 18:1869-1880.
8. Bratt O., Borg A., Kristoffersson U., Lundgren R., Zhang Q.X., Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br. J. Cancer 1999, 81:672-676.
9. Brockschmidt F.F., Nothen M.M., Hillmer A.M. The two most common alleles of the coding GGN repeat in the androgen receptor gene cause differences in protein function. J. Mol. Endocrinol. 2007, 39:1-8.
10. Carter B.S., Beaty T.H., Steinberg G.D., Childs B., Walsh P.C. Mendelian inheritance of familial prostate cancer. Proc. Natl. Acad. Sci. USA 1992, 89:3367-3371.
11. Chamberlain N.L., Driver E.D., Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994, 22:3181-3186.
12. Chang B.L., Zheng S.L., Hawkins G.A., Isaacs S.D., Wiley K.E., Turner A., Carpten J.D., Bleecker E.R., Walsh P.C., Trent J.M., Meyers D.A., Isaacs W.B., Xu J. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res. 2002, 62:1784-1789.
13. Chang B.L., Zheng S.L., Hawkins G.A., Isaacs S.D., Wiley K.E., Turner A., Carpten J.D., Bleecker E.R., Walsh P.C., Trent J.M., Meyers D.A., Isaacs W.B., Xu J. Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum. Genet. 2002, 110:122-129.
14. Chen C., Lamharzi N., Weiss N.S., Etzioni R., Dightman D.A., Barnett M., DiTommaso D., Goodman G. Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2002, 11:1033-1040.
15. Cicek M.S., Conti D.V., Curran A., Neville P.J., Paris P.L., Casey G., Witte J.S. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 2004, 59:69-76.
16. Cicek M.S., Liu X., Casey G., Witte J.S. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2173-2177.
17. Cunningham J.M., Hebbring S.J., McDonnell S.K., Cicek M.S., Christensen G.B., Wang L., Jacobsen S.J., Cerhan J.R., Blute M.L., Schaid D.J., Thibodeau S.N. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2007, 16:969-978.
18. Cussenot O., Azzouzi A.R., Nicolaiew N., Fromont G., Mangin P., Cormier L., Fournier G., Valeri A., Larre S., Thibault F., Giordanella J.P., Pouchard M., Zheng Y., Hamdy F.C., Cox A., Cancel-Tassin G. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J. Clin. Oncol. 2007, 25:3596-3602.
19. Davis D.L., Russell D.W. Unusual length polymorphism in human steroid 5 alpha-reductase type 2 gene (SRD5A2). Hum. Mol. Genet. 1993, 2:820.
20. dos Santos R.M., de Jesus C.M., Trindade Filho J.C., Trindade J.C., de Camargo J.L., Rainho C.A., Rogatto S.R. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy. DNA Cell Biol. 2008, 27:497-503.
21. Douglas J.A., Zuhlke K.A., Beebe-Dimmer J., Levin A.M., Gruber S.B., Wood D.P., Cooney K.A. Identifying susceptibility genes for prostate cancer - a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2035-2039.
22. Edwards S.M., Badzioch M.D., Minter R., Hamoudi R., Collins N., Ardern-Jones A., Dowe A., Osborne S., Kelly J., Shearer R., Easton D.F., Saunders G.F., Dearnaley D.P., Eeles R.A. Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int. J. Cancer 1999, 84:458-465.
23. Elkins D.A., Yokomizo A., Thibodeau S.N., Schaid D.J., Cunningham J.M., Marks A., Christensen E., McDonnell S.K., Slager S., Peterson B.J., Jacobsen S.J., Cerhan J.R., Blute M.L., Tindall D.J., Liu W. Luteinizing hormone beta polymorphism and risk of familial and sporadic prostate cancer. Prostate 2003, 56:30-36.
24. Elo J.P., Harkonen P., Kyllonen A.P., Lukkarinen O., Poutanen M., Vihko R., Vihko P. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res. 1997, 57:3356-3359.
25. Forrest M.S., Edwards S.M., Houlston R., Kote-Jarai Z., Key T., Allen N., Knowles M.A., Turner F., Ardern-Jones A., Murkin A., Williams S., Oram R., Bishop D.T., Eeles R.A. Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis. 2005, 8:95-102. CR-UK/BPG UK prostate cancer study collaborators.
26. Freedman M.L., Pearce C.L., Penney K.L., Hirschhorn J.N., Kolonel L.N., Henderson B.E., Altshuler D. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am. J. Hum. Genet. 2005, 76:82-90.
27. Fukatsu T., Hirokawa Y., Araki T., Hioki T., Murata T., Suzuki H., Ichikawa T., Tsukino H., Qiu D., Katoh T., Sugimura Y., Yatani R., Shiraishi T., Watanabe M. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res. 2004, 24:2431-2437.
28. Fung K.M., Samara E.N., Wong C., Metwalli A., Krlin R., Bane B., Liu C.Z., Yang J.T., Pitha J.V., Culkin D.J., Kropp B.P., Penning T.M., Lin H.K. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr. Relat. Cancer 2006, 13:169-180.
29. Gilligan T., Manola J., Sartor O., Weinrich S.P., Moul J.W., Kantoff P.W. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin. Prostate Cancer 2004, 3:98-103.
30. Giwercman Y.L., Abrahamsson P.A., Giwercman A., Gadaleanu V., Ahlgren G. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur. Urol. 2005, 48:679-685.
31. Giwercman C., Giwercman A., Pedersen H.S., Toft G., Lundin K., Bonde J.P., Lundberg Giwercman Y. Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians. Int. J. Androl. 2008, 31:25-30.
32. Grawford E.D. Epidemiology of prostate cancer. Urology 2003, 62:3-12.
33. Gruber S.B., Chen H., Tomsho L.P., et al. R726L androgen receptor mutation is uncommon in prostate cancer families in the United States. Prostate 2003, 54:306.
34. Gsur A., Preyer M., Haidinger G., Zidek T., Madersbacher S., Schatzl G., Marberger M., Vutuc C., Micksche M. Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis 2002, 23:1647-1651.
35. Hajdinjak T., Zagradisnik B. Prostate cancer and polymorphism D85Y in gene for dihydrotestosterone degrading enzyme UGT2B15: frequency of DD homozygotes increases with Gleason Score. Prostate 2004, 59:436-439.
36. Hayes V.M., Severi G., Eggleton S.A., Padilla E.J., Southey M.C., Sutherland R.L., Hopper J.L., Giles G.G. The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Cancer Epidemiol. Biomarkers Prev. 2005, 14:993-996.
37. Hayes V.M., Severi G., Padilla E.J., Morris H.A., Tilley W.D., Southey M.C., English D.R., Sutherland R.L., Hopper J.L., Boyle P., Giles G.G. 5Alpha-reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int. J. Cancer 2007, 120:776-780.
38. Hsing A.W., Gao Y.T., Wu G., Wang X., Deng J., Chen Y.L., Sesterhenn I.A., Mostofi F.K., Benichou J., Chang C. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res. 2000, 60:5111-5116.
39. Hsing A.W., Chen C., Chokkalingam A.P., Gao Y.T., Dightman D.A., Nguyen H.T., Deng J., Cheng J., Sesterhenn I.A., Mostofi F.K., Stanczyk F.Z., Reichardt J.K. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 2001, 10:1077-1082.
40. Huang S.P., Chou Y.H., Chang W.S., Wu M.T., Yu C.C., Wu T., Lee Y.H., Huang J.K., Wu W.J., Huang C.H. Androgen receptor gene polymorphism and prostate cancer in Taiwan. J. Formos. Med. Assoc. 2003, 102:680-686.
41. Jaffe J.M., Malkowicz S.B., Walker A.H., MacBride S., Peschel R., Tomaszewski J., Van Arsdalen K., Wein A.J., Rebbeck T.R. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res. 2000, 60:1626-1630.
42. Jakobsson J., Palonek E., Lorentzon M., Ohlsson Cm., Rane Am., Ekström L. A novel polymorphism in the 17beta-hydroxysteroid dehydrogenase type 5 (aldo-keto reductase 1C3) gene is associated with lower serum testosterone levels in caucasian men. Pharmacogenomics J. 2007, 7:282-289.
43. Karypidis A.H., Olsson M., Andersson S.O., Rane A., Ekström L. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J. 2007, 8:147-151.
44. Kittles R.A., Chen W., Panguluri R.K., Ahaghotu C., Jackson A., Adebamowo C.A., Griffin R., Williams T., Ukoli F., Adams-Campbell L., Kwagyan J., Isaacs W., Freeman V., Dunston G.M. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?. Hum. Genet. 2002, 110:553-560.
45. Kraft P., Pharoah P., Chanock S.J., Albanes D., Kolonel L.N., Hayes R.B., Altshuler D., Andriole G., Berg C., Boeing H., Burtt N.P., Bueno-de-Mesquita B., Calle E.E., Cann H., Canzian F., Chen Y.C., Crawford D.E., Dunning A.M., Feigelson H.S., Freedman M.L., Gaziano J.M., Giovannucci E., Gonzalez C.A., Haiman C.A., Hallmans G., Henderson B.E., Hirschhorn J.N., Hunter D.J., Kaaks R., Key T., Le Marchand L., Ma J., Overvad K., Palli D., Pike M.C., Riboli E., Rodriguez C., Setiawan W.V., Stampfer M.J., Stram D.O., Thomas G., Thun M.J., Travis R., Trichopoulou A., Virtamo J., Wacholder S. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet. 2005, 1:e68.
46. Kumazawa T., Tsuchiya N., Wang L., Sato K., Kamoto T., Ogawa O., Nakamura A., Kato T., Habuchi T. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int. J. Cancer 2004, 110:140-144.
47. Lamharzi N., Johnson M.M., Goodman G., Etzioni R., Weiss N.S., Dightman D.A., Barnett M., DiTommaso D., Chen C. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer. Int. J. Cancer 2003, 105:480-483.
48. Latil A.G., Azzouzi R., Cancel G.S., Guillaume E.C., Cochan-Priollet B., Berthon P.L., Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001, 92:1130-1137.
49. Li Z., Habuchi T., Mitsumori K., Kamoto T., Kinoshitu H., Segawa T., Ogawa O., Kato T. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J. Urol. 2003, 169:2378-2381.
50. Li L., Cicek M.S., Casey G., Witte J.S. No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2004, 13:2280-2281.
51. Li J., Coates R.J., Gwinn M., Khoury M.J. Steroid 5-{alpha}-reductase type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review. Am. J. Epidemiol. 2009, 171:1-13.
52. Li X., Huang Y., Fu X., Chen C., Zhang D., Yan L., Xie Y., Mao Y., Li Y. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer. Mutagenesis 2011, 26:371-383.
53. Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., Pukkala E., Skytthe A., Hemminki K. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 2000, 343:78-85.
54. Lin C.C., Wu H.C., Chen W.C., Chen H.Y., Tsai F.J. CYP17 gene promoter allelic variant is not associated with prostate cancer. Urol. Oncol. 2003, 21:262-265.
55. Lindstrom S., Zheng S.L., Wiklund F., Jonsson B.A., Adami H.O., Bälter K.A., Brookes A.J., Sun J., Chang B.L., Liu W., Li G., Isaacs W.B., Adolfsson J., Grönberg H., Xu J. Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate 2006, 66:1729-1743.
56. Loukola A., Chadha M., Penn S.G., Rank D., Conti D.V., Thompson D., Cicek M., Love B., Bivolarevic V., Yang Q., Jiang Y., Hanzel D.K., Dains K., Paris P.L., Casey G., Witte J.S. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. Eur. J. Hum. Genet. 2004, 12:321-332.
57. Low Y.L., Taylor J.I., Grace P.B., Mulligan A.A., Welch A.A., Scollen S., Dunning A.M., Luben R.N., Khaw K.T., Day N.E., Wareham N.J., Bingham S.A. Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr. Cancer 2006, 56:31-39.
58. Lu, Y., Sun, J., Kader, A.K., Kim, S.T., Kim, J.W., Liu, W., Sun, J., Lu, D., Feng, J., Zhu, Y., Jin, T., Zhang, Z., Dimitrov, L., Lowey, J., Campbell, K., Suh, E., Duggan, D., Carpten, J., Trent, J.M., Gronberg, H., Zheng, S.L., Isaacs, W.B., Xu, J., 2011. Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses. Prostate, June 10 (Epub ahead of print).
59. MacLeod S.L., Nowell S., Plaxco J., Lang N.P. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Ann. Surg. Oncol. 2000, 7:777-782.
60. Madigan M.P., Gao Y.T., Deng J., Pfeiffer R.M., Chang B.L., Zheng S., Meyers D.A., Stanczyk F.Z., Xu J., Hsing A.W. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Int. J. Cancer 2003, 107:271-275.
61. Makridakis N., Ross R.K., Pike M.C., Chang L., Stanczyk F.Z., Kolonel L.N., Shi C.Y., Yu M.C., Henderson B.E., Reichardt J.K. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res. 1997, 57:1020-1022.
62. Makridakis N.M., Ross R.K., Pike M.C., Crocittom L.E., Kolonel L.N., Pearce C.L., Henderson B.E., Reichardt J.K. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999, 354:975-978.
63. Margiotti K., Kim E., Pearce C.L., Spera E., Novelli G., Reichardt J.K. Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate 2002, 53:65-68.
64. Mhatre A.N., Trifiro M.A., Kaufman M., Kazemi-Esfarjani P., Figlewicz D., Rouleau G., Pinsky L. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat. Genet. 1993, 5:184-188.
65. Mir K., Edwards J., Paterson P.J., Hehir M., Underwood M.A., Bartlett J.M. The CAG trinucleotide repeat length in the androgen receptor does not predict the early onset of prostate cancer. BJU Int. 2002, 90:573-578.
66. Mittal R.D., Mishra D.K., Thangaraj K., Singh R., Mandhani A. Is there an inter-relationship between prostate specific antigen, kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in north Indian population?. Steroids 2007, 72:335-341.
67. Modugno F., Weissfeld J.L., Trump D.L., Zmuda J.M., Shea P., Cauley J.A., Ferrell R.E. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin. Cancer Res. 2001, 7:3092-3096.
68. Mononen N., Syrjakoski K., Matikainen M., Tammela T.L., Schleutker J., Kallioniemi O.P., Trapman J., Koivisto P.A. Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res. 2000, 60:6479-6481.
69. Mononen N., Ikonen T., Syrjakoski K., Matikainen M., Schleutker J., Tammela T.L., Koivisto P.A., Kallioniemi O.P. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br. J. Cancer 2001, 84:1344-1347.
70. Mononen N., Seppala E.H., Duggal P., Autio V., Ikonen T., Ellonen P., Saharinen J., Saarela J., Vihinen M., Tammela T.L., Kallioniemi O., Bailey-Wilson J.E., Schleutker J. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res. 2006, 66:743-747.
71. Nam R.K., Toi A., Vesprini D., Ho M., Chu W., Harvie S., Sweet J., Trachtenberg J., Jewett M.A., Narod S.A. V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 2001, 57:199-204.
72. Nam R.K., Zhang W.W., Trachtenberg J., Jewett M.A., Emami M., Vesprini D., Chu W., Ho M., Sweet J., Evans A., Toi A., Pollak M., Narod S.A. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2003, 12:1429-1437.
73. Ntais C., Polycarpou A., Ioannidis J.P. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2003, 12:120-126.
74. Ntais C., Polycarpou A., Ioannidis J.P. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 2003, 12:618-624.
75. Okugi H., Nakazato H., Matsui H., Ohtake N., Nakata S., Suzuki K. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population. Cancer Detect. Prev. 2006, 30:262-268.
76. Paris P.L., Kupelian P.A., Hall J.M., Williams T.L., Levin H., Klein E.A., Casey G., Witte J.S. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomarkers Prev. 1999, 8:901-905.
77. Park J., Chen L., Shade K., Lazarus P., Seigne J., Patterson S., Helal M., Pow-Sang J. Asp85tyr polymorphism in the UDP-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J. Urol. 2004, 171:2484-2488.
78. Park J.Y., Tanner J.P., Sellers T.A., Huang Y., Stevens C.K., Dossett N., Shankar R.A., Zachariah B., Heysek R., Pow-Sang J. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology 2007, 70:374-379.
79. Plummer S.J., Conti D.V., Paris P.L., Curran A.P., Casey G., Witte J.S. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2003, 12:928-932.
80. Powell I.J., Zhou J., Sun Y., Sakr W.A., Patel N.P., Heilbrun L.K., Everson R.B. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J. Urol. 2004, 172:1848-1852.
81. Rebbeck T.R., Jaffe J.M., Walker A.H., Wein A.J., Malkowicz S.B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 1998, 90:1225-1229.
82. Risio, M., Venesio, T., Kolomoets, E., Armaroli, P., Gallo, F., Balsamo, A., Muto, G., D'Urso, L., Puppo, P., Naselli, A., Segnan, N., BECaP Working Group, 2010. Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers. Cancer Epidemiol., November 18 (Epub ahead of print).
83. Ross R.W., Oh W.K., Xie W., Pomerantz M., Nakabayashi M., Sartor O., Taplin M.E., Regan M.M., Kantoff P.W., Freedman M. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J. Clin. Oncol. 2008, 26:842-847.
84. Sarma A.V., Dunn R.L., Lange L.A., Ray A., Wang Y., Lange E.M., Cooney K.A. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate 2008, 68:296-305.
85. Sasaki M., Nomoto M., Yonezawa S., Nakagawa M., Sakuragi N., Fujimoto S., Carroll P.R., Dahiya R. Distribution of a single nucleotide polymorphism on codon 211 of the androgen receptor gene and its correlation with human renal cell cancer in Japanese patients. Biochem. Biophys. Res. Commun. 2004, 321:468-471.
86. Schaid D. The complex genetic epidemiology of prostate cancer. Hum. Mol. Genet. 2004, 13:R103-R121. Spec. No. 1.
87. Setlur S.R., Chen C.X., Hossain R.R., Ha J.S., Van Doren V.E., Stenzel B., Steiner E., Oldridge D., Kitabayashi N., Banerjee S., Chen J.Y., Schäfer G., Horninger W., Lee C., Rubin M.A., Klocker H., Demichelis F. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2010, 19:229-239.
88. Sieh W., Edwards K.L., Fitzpatrick A.L., Srinouanprachanh S.L., Farin F.M., Monks S.A., Kronmal R.A., Eaton D.L. Genetic susceptibility to prostate cancer: prostate-specific antigen and its interaction with the androgen receptor (United States). Cancer Causes Control 2006, 17:187-197.
89. Siemens C., Visser L.E., de Jong F.H., Coebergh J.W., Uitterlinden A.G., Hofman A., Stricker B.H., van Schaik R.H. Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer - The Rotterdam Study. Steroids 2010, 75:1024-1032.
90. Soderstrom T., Wadelius M., Andersson S.O., Johansson J.E., Johansson S., Granath F., Rane A. 5Alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002, 12:307-312.
91. Sonoda T., Suzuki H., Mori M., Tsukamoto T., Yokomizo A., Naito S., Fujimoto K., Hirao Y., Miyanaga N., Akaza H. Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men. Eur. J. Cancer Prev. 2010, 19:131-137.
92. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., Febbo P.G., Balk S.P. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006, 66:2815-2825.
93. Stone A., Ratnasinghe L.D., Emerson G.L., Modali R., Lehman T., Runnells G., Carroll A., Carter W., Barnhart S., Rasheed A.A., Greene G., Johnson D.E., Ambrosone C.B., Kadlubar F.F., Lang N.P. CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians. Cancer Epidemiol. Biomarkers Prev. 2005, 14:1257-1261.
94. Suzuki K., Nakazato H., Matsui H., Koike H., Okugi H., Kashiwagi B., Nishii M., Ohtake N., Nakata S., Ito K., Yamanaka H. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer 2003, 98:1411-1416.
95. Thomae B.A., Eckloff B.W., Freimuth R.R., Wieben E.D., Weinshilboum R.M. Human sulfotransferase SULT2A1 pharmacogenetics: genotype-to-phenotype studies. Pharmacogenomics J. 2002, 2:48-56.
96. Travis R.C., Schumacher F., Hirschhorn J.N., Kraft P., Allen N.E., Albanes D., Berglund G., Berndt S.I., Boeing H., Bueno-de-Mesquita H.B., Calle E.E., Chanock S., Dunning A.M., Hayes R., Feigelson H.S., Gaziano J.M., Giovannucci E., Haiman C.A., Henderson B.E., Kaaks R., Kolonel L.N., Ma J., Rodriguez L., Riboli E., Stampfer M., Stram D.O., Thun M.J., Tjønneland A., Trichopoulos D., Vineis P., Virtamo J., Le Marchand L., Hunter D.J. CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2734-2744.
97. Turgeon D., Carrier J.S., Levesque E., Hum D.W., Bélanger A. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 2001, 142:778-787.
98. Vaarala M.H., Mattila H., Ohtonen P., Tammela T.L., Paavonen T.K., Schleutker J. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. Int. J. Cancer 2008, 122:2511-2516.
99. Varghese S.J., Easton D.F. Genome-wide association studies in common cancers - what have we learnt?. Curr. Opin. Genet. Dev. 2010, 20:201-209.
100. Vesovic Z., Herkommer K., Vogel W., Paiss T., Maier C. Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany. Anticancer Res. 2005, 25:1303-1307.
101. Walker A.H., Jaffe J.M., Gunasegaram S., Cummings S.A., Huang C.S., Chern H.D., Olopade O.I., Weber B.L., Rebbeck T.R. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191 (online). Hum. Mutat. 1998, 12:289.
102. Wilborn T.W., Lang N.P., Smith M., Meleth S., Falany C.N. Association of SULT2A1 allelic variants with plasma adrenal androgens and prostate cancer in African American men. J. Steroid Biochem. Mol. Biol. 2006, 99:209-214.
103. Wirth M.P., See W.A., McLeod D.G., Iversen P., Morris T., Carroll K. Bicalutamide 150mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J. Urol. 2004, 172(5 Pt. 1):1865-1870. Casodex Early Prostate Cancer Trialists' Group.
104. Wright J.L., Kwon E.M., Lin D.W., Kolb S., Koopmeiners J.S., Feng Z., Ostrander E.A., Stanford J.L. CYP17 polymorphisms and prostate cancer outcomes. Prostate 2010, 70:1094-1101.
105. Yamada Y., Watanabe M., Murata M., Yamanaka M., Kubota Y., Ito H., Katoh T., Kawamura J., Yatani R., Shiraishi T. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int. J. Cancer 2001, 92:683-686.
106. Zeegers M.P., Kiemeney L.A., Nieder A.M., Ostrer H. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk?. Cancer Epidemiol. Biomarkers Prev. 2004, 13:1765-1771.
107. Zeigler-Johnson C., Friebel T., Walker A.H., Wang Y., Spangler E., Panossian S., Patacsil M., Aplenc R., Wein A.J., Malkowicz S.B., Rebbeck T.R. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 2004, 64:8461-8467.
108. Zubiaga A.M., Belasco J.G., Greenberg M.E. The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol. Cell. Biol. 1995, 15:2219-2230.